Neurobiological Mechanisms in Depression Treatment

Depression is a debilitating psychiatric disorder characterised by persistent low mood, anhedonia and cognitive impairments. Neurobiological investigations have identified dysregulation across multiple systems, including synaptic connectivity, neuroinflammatory cascades and neuromodulator pathways. Alterations in glutamatergic signalling and synaptic plasticity in the prefrontal cortex and hippocampus underpin both the pathogenesis and therapeutic responses. Fast-acting antidepressants such as ketamine and its enantiomer esketamine evoke rapid synaptic remodelling via activation of molecular cascades involving mTOR, ERK1/2 and neurotrophic factors. Concurrently, chronic inflammation and peripheral immune activation can disrupt tryptophan metabolism and reduce neuroplasticity. Modulation of the gut–brain axis through probiotic and nutraceutical interventions offers complementary avenues for intervention. Together, these converging lines of enquiry underscore an integrated framework in which synaptic restoration, anti-inflammatory processes and metabolic regulation form the cornerstone of contemporary and emerging depression treatments.

Research from Nature Portfolio

Recent studies have elucidated how low-dose ketamine rapidly restores glutamatergic synapses in the infralimbic prefrontal cortex by enhancing planar cell polarity signalling in neurons projecting to the basolateral amygdala, thereby reversing behavioural deficits in a mouse model of chronic stress. Conditional deletion of key polarity proteins abolished both synaptic and behavioural restoration, revealing a mechanistic link between PCP pathway regulation and ketamine’s sustained antidepressant effects. In parallel, investigations of esketamine demonstrate that its anxiolytic and antidepressant actions engage the PGC-1α/irisin/ERK1/2 axis. In chronic stress paradigms, esketamine rescues diminished PGC-1α and irisin levels in the hippocampus, activating ERK1/2 and ameliorating depressive-like behaviours. Genetic ablation of the FNDC5 gene, which encodes the irisin precursor, attenuates these effects, highlighting irisin as a potential therapeutic target for depression.

Neurobiological Mechanisms in Depression Treatment publication trend

The graph below shows the total number of articles in neurobiological mechanisms in depression treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Glutamatergic synapses: Synaptic junctions that use glutamate as the neurotransmitter, critical for excitatory signalling and plasticity in the brain.

Planar cell polarity (PCP) signalling: A molecular pathway governing the organisation and orientation of cells, implicated in synapse formation and stability.

PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, a transcriptional regulator of energy metabolism and neurotrophic factor expression.

Irisin: A myokine derived from FNDC5 that is upregulated by PGC-1α and mediates neuroprotective and synaptic plasticity effects.

ERK1/2 pathway: Extracellular signal-regulated kinase cascade involved in cell survival, growth and synaptic modulation.

Neuroinflammation: Inflammatory responses within the central nervous system driven by activated glial cells and cytokine release.

Gut microbiota dysbiosis: Imbalance in intestinal microbial communities that can affect brain function via immune and metabolic pathways.

Pro-inflammatory cytokines: Signalling proteins such as IL-1β, IL-6 and TNF-α that mediate and amplify inflammatory responses.

Nitric oxide species (NOx): Reactive nitrogen metabolites involved in vasodilation, neurotransmission and oxidative stress regulation.

References

1. Planar cell polarity proteins mediate ketamine-induced restoration of glutamatergic synapses in prefrontal cortical neurons in a mouse model for chronic stress. Nature Communications (2024).
2. Exploring the role of esketamine in alleviating depressive symptoms in mice via the PGC-1α/irisin/ERK1/2 signaling pathway. Scientific Reports (2023).
3. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets. Cells (2024).
4. Vitamins C and D Exhibit Similar Antidepressant Effects to Escitalopram Mediated by NOx and FKBPL in a Stress-Induced Mice Model. Nutrients (2023).
5. Exploring the Roles of Vitamins C and D and Etifoxine in Combination with Citalopram in Depression/Anxiety Model: A Focus on ICAM-1, SIRT1 and Nitric Oxide. International Journal of Molecular Sciences (2024).